Angiogenesis requires the elaboration of endothelium-derived nitric oxide (NO). Angiogenic factors induce the release of NO from endothelial cells, which mediates a multiplicity of processes involved in angiogenesis. These NO-modulated processes include endothelial cell survival, proliferation, migration, and interaction with the extracellular matrix. Derangements of the NO synthase pathway impair angiogenesis. Accordingly, the competitive inhibitor of the NOS pathway asymmetric dimethylarginine (ADMA) acts as an endogenous inhibitor of angiogenesis. By contrast, agents which increase NO synthesis, such as low dose statins, enhance angiogenesis. Modulation of the NO synthase pathway could become a new therapeutic avenue for angiogenesis-related disorders.

Original languageEnglish (US)
Pages (from-to)53-60
Number of pages8
JournalAtherosclerosis Supplements
Issue number4
StatePublished - Dec 2003


  • Angiogenesis
  • Asymmetric dimethylarginine
  • HMG coA reductase inhibition
  • L-Arginine
  • NOS

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'NO and angiogenesis'. Together they form a unique fingerprint.

Cite this